ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 98 filers reported holding ASCENDIS PHARMA A/S in Q3 2018. The put-call ratio across all filers is 1.39 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $348,000 | -4.7% | 3,608 | +13.9% | 0.01% | 0.0% |
| Q2 2019 | $365,000 | +4.3% | 3,168 | +6.7% | 0.01% | 0.0% |
| Q1 2019 | $350,000 | +35.1% | 2,970 | -28.2% | 0.01% | +16.7% |
| Q4 2018 | $259,000 | -49.0% | 4,136 | -42.3% | 0.01% | -40.0% |
| Q3 2018 | $508,000 | +10.0% | 7,172 | +3.2% | 0.01% | 0.0% |
| Q2 2018 | $462,000 | +13.8% | 6,952 | +12.1% | 0.01% | +150.0% |
| Q1 2018 | $406,000 | – | 6,204 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
| Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
| Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
| Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
| Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
| Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
| Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
| DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
| ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
| Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |